This is a randomized trial of the use of Albuterol in the setting of acute decompensated Congestive Heart Failure with radiographic evidence of Cardiogenic Pulmonary Edema.
The objective is to carry out a randomized blinded placebo-controlled trial of inhaled Albuterol as an early therapy for patients with decompensated Congestive Heart Failure. Compared to placebo, inhaled Albuterol will improve oxygenation and decrease the need for non-invasive ventilation in patients with Cardiogenic Pulmonary Edema.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
University of California
San Francisco, California, United States
Borg Dyspnea Score
Patients are evaluated for approximatly 8 hours with the Borg Dyspnea Score. Starting at the time of arrival, then one hour later and consequently every two hours until reaching 8 hours in total. The Borg score is used to quantify the degree of shortness of breath a person is experiencing which is a measured on a 10 point visual-analog scale.
Time frame: 8 hours.
Admission
If the patient is hospitalized we will continue to record information about their hospital stay and the patient will not receive more study interventions.
Time frame: An average of 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.